NSA Minute: IDR Surprises
The Independent Dispute Resolution (IDR) process for NSA continues to deliver surprises and complexities for payers. For example, in a…
The Independent Dispute Resolution (IDR) process for NSA continues to deliver surprises and complexities for payers. For example, in a…
Legal challenges to the No Surprises Act (NSA) continue to arise with six lawsuits brought forth so far. One lawsuit…
At the end of 2022, half of hospitals are in the red — putting pressure on hospitals to look for…
As we follow the impact of NSA, we continue to see unexpected scenarios occur. For example, with out-of-network at an…
The recent No Surprises Act’s (NSA) report from HHS, Department of Labor, and Department of the Treasury presented eye-opening statistics…
As our hearts and prayers go out to Damar Hamlin and his family for a speedy recovery after his on-field…
Calculating accurate QPAs is difficult and mistakes can be costly and create compliance risks. Here's what to do.
The use of biosimilar products in lieu of originator biologic products has been a hot topic of discussion since the…
The biologics market could see some significant changes with the current and upcoming interchangeability approvals of several biosimilar products. Let’s…